Heart Failure

The FDA has identified Boston Scientific’s recall of certain pacemakers or cardiac resynchronization therapy pacemakers as class I, the most serious type, due to risk of incorrect transition to safety mode.

In patients diagnosed with atrial fibrillation for less than 1 year, those with HF benefited from rhythm control therapy compared with the usual care, according to new data from the EAST-AFNET 4 trial.

A new cost-utility analysis has shown that catheter ablation as a second-line intervention is likely cost-effective for patients with HF and symptomatic atrial fibrillation.

In the VITAL trial, marine omega-3 fatty acids did not prevent stroke, but they did reduce the risk for myocardial infarction compared with an olive oil placebo. A review of the data was the top story in cardiology last week.

HF is a growing economic burden in the U.S., with 1 million new cases projected to surface in 2021; however, there is a paucity of guidance on HF prevention, a speaker reported.

Biofourmis announced that its software application to help manage medical therapy in patients with HF has received a breakthrough device designation from the FDA.

Despite secondary mitral regurgitation in patients with HF being common and associated with mortality, surgical or transcatheter valve repair was seldom performed in this population, researchers reported.

Women and Black individuals are more likely to be diagnosed with HF in an acute care setting than a primary care setting compared men and white patients, respectively, according to data published in Circulation: Heart Failure.

Readmission rate for those with hidradenitis suppurativa may be comparable to the rate for those with heart failure at 180 days, according to a short communication analysis published in the Journal of the American Academy of Dermatology.

The “ABCs” have provided a roadmap for primary and secondary CVD prevention since 1999, according to a speaker at the virtual American Society for Preventive Cardiology Congress on CVD Prevention.